Table 2 Demographic data at diagnosis and follow-up in primary HT children with controlled and uncontrolled HT

At diagnosis

Age, y (mean ± SD)

12.2 ± 3.67

13.09 ± 3.22

11.48 ± 3.9

0.11

Male, N (%)

40 (71.4)

19 (76)

21 (67.7)

0.56

Diagnosis BMI z-score, median (IQR)

2.5

(1.45, 2.86)

2.51

(1.43, 2.78)

2.5

(1.35, 3.18)

0.79

Office SBP index, median (IQR)

1.04 (1, 1.08)

1.04 (1, 1.09)

1.03 (1, 1.08)

0.66

Office DBP index, median (IQR)

0.96 (0.91, 1.04)

0.97 (0.9, 1.05)

0.96 (0.91, 1.04)

0.81

eGFR (ml/min/1.73m²), mean ± SD

N = 52

108.89 ± 27.05

N = 24

103.3 ± 30.12

N = 28

113.68 ± 23.62

0.17

At Follow-up

Age, y (mean ± SD)

13.91 ± 3.86

14.72 ± 3.34

13.25 ± 4.17

0.16

The 1st ABPM after treating HT (y), median (IQR)

1 (0.5, 2.18)

1.11 (0.5, 2.5)

0.9 (0.4, 2)

0.62

BMI z score, mean ± SD

2.13 ± 1.56

1.96 ± 1.06

2.26 ± 1.87

0.49

BMI z score change, median (IQR)

-0.14

(-0.51, 0.14)

-0.39

(-0.57, 0.12)

0.01

(-0.39, 0.22)

0.032*

24-hr ABPM SBP index, mean ± SD

0.98 ± 0.08

0.92 ± 0.05

1.04 ± 0.06

< 0.001

24-hr ABPM DBP index, mean ± SD

0.89 ± 0.08

0.85 ± 0.05

0.93 ± 0.07

< 0.001

eGFR (ml/min/1.73m²), median (IQR)

N = 49

106.49

(90.94,120.32)

N = 19

105.94

(84.37, 119.69)

N = 30

108.06

(91.57, 122.81)

0.4

eGFR change (ml/min/1.73m²), median (IQR)

N = 45

0.36

(-17.46, 9.52)

N = 19

-5.18

(-22.01, 11.76)

N = 26

1.23

(-15.62, 9.05)

0.37

Number of anti-HT drugs per patient, mean ± SD

N = 41

1.34 ± 0.53

N = 17

1.35 ± 0.49

N = 24

1.33 ± 0.57

0.91

Proteinuria, N (%)

N = 7

1 (14.29)

N = 3

0 (0)

N = 4

1 (25)

0.35

ACEI monotherapy, N

7

4

3

0.26

ARB monotherapy, N

2

2

0

0.07

CCB monotherapy, N

15

5

10

0.49